Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 348 participants.
Also called NCT02917031
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 348 participants
- Sponsor
- Registry
-
NCT02917031
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Chile, Hungary, Romania, Russia, South Korea, Thailand, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02917031. Randomized; triple masking; primary purpose treatment. Start 2017-01-10 (actual); primary completion 2019-08-23 (actual). Results posted on 2021-06-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
- Acronym
- MEASURE-HF
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Heart Failure
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo to match saxagliptin
- Intervention (Drug)
- Placebo to match sitagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02917031- Content hash
9d91d758d7f1a937eb0755c35af5e2b96c65dc35ff2642dd0b9108eefdebd7ad